AzTrials
AzTrials

Noninvasive Positive Pressure VentilationSAFE-NIVNCT03066934

A Multicentered Study on Efficiency of Noninvasive Ventilation Procedures

An observational study of Noninvasive Positive Pressure Ventilation and High Flow Nasal Cannula, run by Akdeniz University at 2 sites in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Noninvasive ventilation (NIV) is an alternative form of ventilatory support in critical care encompassing different modes of ventilation such as continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP) and high flow nasal cannula ventilation. Read more about this study

Who is it for?
Ages 1 month to 18 years
What is being tested?
noninvasive ventilation respiratory support
How many people
352 participants
Where
2 sitesTurkey (Türkiye)
Study dates
Nov 2016to Nov 2018
How long will I take part?
5 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: all noninvasively ventilated children from one month to eighteen years will be enrolled in this study

Who may be able to join

  • noninvasively ventilated children
  • age: 1 month - less than 18 years

Who cannot join

None listed.

Trial locations and contacts

2 sites in 1 country.

Turkey (Türkiye)2 sites
  • Akdeniz University Faculty of Medicine Department of Pediatrics Division of Pediatric Critical Care

    Antalya, 07059

  • Akdeniz University Faculty of Medicine

    Antalya, 07059

Other trials in Turkey (Türkiye)

About this study

Noninvasive ventilation (NIV) is an alternative form of ventilatory support in critical care encompassing different modes of ventilation such as continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP) and high flow nasal cannula ventilation. Although numerous studies on adults exit in literature, the aspects of this ventilatory support is limited in pediatric age groups. Early recognition of respiratory failure and initiation of NIV in a pediatric patient would positively affect prognosis by avoiding certain complications of endotracheal intubation and mechanical ventilation and adds certain advantages. Decreasing re-intubation rates for the ones who are extubated but necessitating further oxygen support is another advantage of NIV. Although numerous studies on adults exit in literature, the aspects of this ventilatory support is limited in pediatric age groups. Besides, success as well as failure and complication rates in pediatric age groups vary extensively. This multi-centered, prospective cohort study is planned to observe the epidemiologic perspectives of study group within underlying problems, success rates between different age groups, complication and re-intubation rates and finally its' effect on prognosis and long term survival in a year period. Hence we believe results of this study would allow us to improve our knowledge on using this technique, applying different modes and parameters appropriately and design criteria to guide clinician in deciding which group of patients would benefit from NIV techniques.

Read the detailed description

Total of 9 pediatric critical care centers all across the country will collaborate at this study:

  1. Akdeniz University Faculty of Medicine, Pediatric Critical Care Division
  2. Cukurova University Faculty of Medicine, Pediatric Critical Care Division
  3. Ege University Faculty of Medicine, Pediatric Critical Care Division
  4. Ankara University Faculty of Medicine, Pediatric Critical Care Division
  5. Ondokuz Mayis University Faculty of Medicine, Pediatric Critical Care Division
  6. Erciyes University Faculty of Medicine, Pediatric Critical Care Division
  7. Koc University Faculty of Medicine, Pediatric Critical Care Division
  8. Dokuz Eylül University Faculty of Medicine, Pediatric Critical Care Division
  9. Izmir Katip Celebi University Faculty of Medicine, Pediatric Critical Care Division Since nature of this study is an observational cohort, all noninvasively ventilated children from one month to eighteen years will be enrolled in this study. A three-page questionnaire is designed to collect data. The first page includes information on epidemiological data, underlying disease in terms of both acute and chronicle problems resulting in respiratory problems; the second page includes a multi-colon table to record vital signs (heart and respiratory rate, systemic and diastolic blood pressure), PRISM-III and Pediatric logistic organ dysfunction (PELOD) scores, Glasgow coma scale, blood gas values, ventilation parameters, necessity of sedation (if so, drugs used for sedation) and finally comfort pain scores. Data will be collected immediately prior to commencing NIV, the first, second and sixth hours; if NIV support continues over 24 hours, then daily data will be obtained up to five days. Last questionnaire page consists of data for clinical outcome, reason of NIV failure, necessity of re-intubation and if so timing of re-intubation.

Primary outcome of this study is to observe success rates in decreasing necessity of mechanical ventilation or re-intubation. Successfully managed children will also be evaluated for age groups, underlying disease as well as modes of delivery and ventilation parameters to define thresholds on decision of NIV success or failure. Secondary outcome is to evaluate the NIV failure in terms of pediatric age groups, underlying disease, rates of NIV-related complications. If a respiratory failure occurs, modes of delivery and ventilation parameters, usage of different masks, timing of failure decision according to patients' clinical data will be explored from collected data.

Each center will fill in the questionnaire according to patient data and every two months period data will be collected from collaborators. After one year period, statistical evaluation will be investigated by the principle investigators.

Below participants may observe the questionnaire form:

Form - I

  1. Age (months):
  2. Sex:
  3. Weight (kg):
  4. PRISM - III score
  5. Which one of the following describes the underlying disease? i. What is the acutely-developed illness that required noninvasive ventilation? (Can be marked more than one option)
  6. Heart failure
  7. Pneumonia
  8. Bronchiolitis /Asthma
  9. Acute respiratory distress syndrome (ARDS)
  10. Sepsis
  11. Laryngeal stridor after extubation (or respiratory distress)
  12. Other (please describe) : ii. What is the chronic underlying disease (Primary disease which occurred previously) (can be marked more than one option)
  13. Neuromotor disease
  14. Metabolic disease
  15. Malignancy
  16. Congenital cardiac disease
  17. Chronic pulmonary disease
  18. Immune deficiency
  19. Other (please specify)
  20. No chronic underlying disease
  21. What is the type of respiratory insufficiency?
  22. Hypoxemic (Type I)
  23. Hypercapnic (Type II)
  24. Was the patient intubated before noninvasive ventilation?
  25. Yes
  26. No
  27. If participant's answer is YES to previous question, please describe the length of intubation period (hours):
  28. Which one of the following describes NIV device?
  29. Specific noninvasive ventilation device
  30. Conventional mechanical ventilator with the noninvasive mode
  31. High flow nasal cannula
  32. BIPAP device (without oxygen blender)
  33. Other:
  34. Which one of the mask types did participant apply in the patient?
  35. Nasal mask
  36. Oronasal mask
  37. Full face mask
  38. Nasal prong (cannula)
  39. Endotracheal tube
  40. Other (please specify):

Form - II: Variables attached below will be recorded at initial, first, second, sixth, 24th, 48th, 72th, 96th, 120th hours.

  • Respiratory rate
  • Heart rate
  • Systolic tension
  • Mean tension
  • Diastolic tension
  • PRISM - III score
  • PELOD score
  • Glasgow coma score
  • Blood gas (arterial/ venous/ capillary)
  • Partial arterial oxygen concentration (PaO2) / Fraction of Inspired oxygen (FiO2)
  • Oxygen saturation (SpO2) / Fraction of Inspired oxygen ( FiO2)
  • Partial arterial carbon dioxide concentration (PaCO2)
  • Power of Hydrogen (pH)
  • Device Mode
  • Inspiratory positive airway pressure (IPAP) value
  • Expiratory positive airway pressure (EPAP) value
  • Fraction of inspired oxygen (FiO2) value
  • Inspiratory time (IT)
  • Rise time value
  • Tidal volume
  • Leakage (%)
  • Mandatory rate
  • High flow rate
  • Sedo-analgesia drugs and dosage
  • Comfort score

Form - III

  1. Please select your observation on NIV success.
  2. Patient had to be re-intubated after 48 hours of NIV.
  3. Patient was successfully withdrawn from NIV in 48 hours.
  4. Patient received noninvasive ventilation for ……………………days.
  5. If participant's answer is 'A' to the previous question, please specify the reason of re-intubation below (can be marked more than once)
  6. Patient - ventilator asynchrony
  7. Face - mask mismatch
  8. Significant leakage percentage
  9. Progress to respiratory failure (can be marked more than once) (i) SpO2/FiO2<193 in 0-1 hour (ii) FiO2 necessity > %80 (iii) Blood gas power of hydrogen (pH) <7.25 in two hours (iv) Failure to achieve 10% expected decrease in respiratory rate at second and sixth hours (v) Increase in clinically observed respiratory effort (vi) Progression to severe ARDS (Oxygenation index > 8)
  10. Neurologically deteriorating patient (Glasgow coma score < 8 or deterioration over three units)
  11. Risk of aspiration or bulbar dysfunction (loss of swallowing)
  12. Hemodynamic instability
  13. Arrythmia
  14. Pneumothorax
  15. Other (please specify):
  16. If participant observes a complication in the patient, please specify below (can be marked more than once).
  17. Loss of skin intact
  18. Pneumothorax
  19. Puking and aspiration pneumonia
  20. Hemodynamic instability
  21. Other (please specify): ……………….................
  22. No complication was observed.
  23. Please specify the length of noninvasive ventilation ………………………….. (hours)
  24. If patient received NIV breaks in a day, please write down the length of ventilation hours per day. Day 1:……………………………… Day 2: …………………………………...
  25. What is clinical outcome of the patient after noninvasive ventilation support?
  26. Respiratory failure diminished and patient was discharged from Pediatric intensive care unit (PICU) after ……………. (days / hours) .
  27. Patient was discharged form PICU with home- style noninvasive device after …………… days/hours)
  28. Patient necessitated tracheostomy.
  29. Patient died of respiratory failure after ………………. days/hours.
  30. What is the length of hospital discharge? (please specify): …………………….
Being tested
noninvasive ventilation respiratory support
Keywords
Noninvasive Positive Pressure Ventilation, Nasal high flow, Respiratory Failure, Childhood
Medical subject headings
Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • noninvasive ventilation respiratory supportOther

Study groups in NCT03066934
Study groupRoleWhat they receive
NIV Failure GroupNIV Failure Group consisted of children who failed their noninvasive ventilation session and required intubation or re-intubation
Receives: Other: noninvasive ventilation respiratory support
NIV success groupChildren who successfully managed their noninvasive ventilation therapy
Receives: Other: noninvasive ventilation respiratory support

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine the incidence of NIV failure in children requiring invasive mechanical ventilation

    NIV failure is defined as necessity of endotracheal intubation due to respiratory insufficiency within 48 hours in children receiving noninvasive ventilation in pediatric critical care units. Statistical analysis will be performed according to answers to form-I question-6 and form-III question-1 in the questionnaire.

    Measured: one year

  2. To determine the incidence of NIV failure as re-intubation within 48 hours.

    NIV failure is also determined as re-intubation within 48 hours for those who were previously intubated and received noninvasive ventilation following extubation. Second primary outcome will be evaluated by Form - I question-6 and Form - III question-1.

    Measured: 1 year

Secondary outcomes (4)
  1. To determine the reasons resulting in NIV failure in children enrolled in the study

    Reasons of NIV failure is classified as; patient - ventilator asynchrony, face-mask mismatch, significant leakage percentage, progression to respiratory insufficiency [SpO2/FiO2<193 within the first hour; FiO2 necessity > %80 within two hours; blood gas pH<7.25 within two hours; failure to achieve 10 % expected decrease in respiratory rate within sixth hours, increase in clinically observed respiratory effort or progression to severe ARDS (Oxygenation index > 8)], neurologically deteriorating patient (Glasgow coma score < 8 or a decrease in score more than three units), risk of aspiration or bulbar dysfunction (loss of swallowing), hemodynamic instability, presence of arrhythmia and pneumothorax. Underlying causes of NIV failure will be evaluated by answers to question-2 in Form III.

    Measured: one year

  2. To explore complication rates directly related to noninvasive ventilation.

    Complications related to noninvasive ventilation are loss of skin intact, development of pneumothorax, puking and related aspiration pneumonia, and hemodynamic instability. Form - III question 3 will enlighten the incidence and the variety of complications.

    Measured: one year

  3. To observe NIV success for those who receive noninvasive ventilation over 48 hours

    Evaluation of answers to Form III questions 4-5-6 will demonstrate the NIV success for those who receive noninvasive ventilation over 48 hours as the third secondary outcome. Daily ventilation breaks and length of noninvasive support per day (day 1 to day 5) will also be recorded by investigators to investigate the association of NIV success and noninvasive durations by applying multiple logistic regression analysis.

    Measured: one year

  4. To explore prognosis of patients receiving noninvasive ventilation

    Final secondary outcome will be the exploration of prognosis and the interactions between efficiency of noninvasive ventilation by length of intensive care unit and hospital stay and as well as mortality regarding answers to questions six and seven in Form -III.

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Mar 2017
  2. Study startNov 2016
  3. Primary completionDec 2017
  4. Study completionNov 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
352 participants (actual)
Target duration
5 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT03066934
Sponsor's protocol ID
70904504/525
Acronym
SAFE-NIV
Status last verified
Sep 2019
First submitted
3 Feb 2017
Last updated
10 Sep 2019
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Noninvasive Positive Pressure Ventilation and High Flow Nasal Cannula, run by Akdeniz University at 2 sites in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine the incidence of NIV failure in children requiring invasive mechanical ventilation (time frame: one year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in